Clinical trial
Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer
NCT00003343 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00003343 |
|---|---|
| Title | Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of the Matrix Metalloprotease Inhibitor AG3340 in Combination With Mitoxantrone and Prednisone With Provision for Subsequent Change in Therapy in Patients Having Hormone-Refractory Prostate Cancer |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | endocrine-modulating drug therapy, mitoxantrone hydrochloride, prednisone, prinomastat |
| Enrollment | 525 |
| Start date | Mar 1, 1998 |
| Primary completion | Jan 1, 2001 |
| First posted | Jul 16, 2004 |
| Last update posted | Aug 8, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: